OTCM
PCYN
Market cap982kUSD
Nov 03, Last price
0.12USD
Name
Procyon Corp
Chart & Performance
P/E
28.99
P/S
0.15
EPS
0.00
Div Yield, %
—
Shrs. gr., 5y
0.28%
Rev. gr., 5y
9.02%
Revenues
7m
+33.89%
Net income
34k
P
CFO
-441k
L+619.74%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Procyon Corporation, along with its affiliated entities, specializes in the development and distribution of proprietary medical solutions. Their primary focus is on addressing various skin conditions, including pressure and stasis ulcers, general wounds, dermatitis, inflammation, and other dermatological issues, predominantly within the United States. The company offers a diverse array of products. Under the AMERIGEL brand, they provide sophisticated skin and wound healing items such as hydrogel dressings, post-operative surgical kits, saline wound rinses, and protective lotions, in addition to hand sanitizer. Their HELIX3 line features Bioactive Collagen products, available in both powder and matrix forms. For comprehensive wound management, the AMERX brand includes various dressing types like calcium alginate, foam, gauze, and hydrocolloid, as well as complete wound care kits containing components like collagen matrix, collagen powder, foam, and hydrogel. Furthermore, Procyon markets compression garments under the EXTREMIT-EASE name. These offerings are distributed through multiple channels: to institutional clients such as hospitals, wound care clinics, nursing homes, home health agencies, and medical practitioners via distributors, and directly to individual consumers through online sales, direct purchases, and independent or chain pharmacies. Founded in 1987, the company's operations are headquartered in Clearwater, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||